What are the normal findings on pulmonary function tests in an adult, and what pulmonary function test criteria indicate that bleomycin should be held in a patient with a germ‑cell tumor?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Normal PFT Findings and Bleomycin Holding Criteria in Germ Cell Tumors

PFTs should NOT be used in isolation to decide whether to hold bleomycin in germ cell tumor patients—clinical symptoms (especially new cough or dyspnea) and HRCT imaging are the primary indicators for holding bleomycin, not PFT values alone. 1

Normal Pulmonary Function Test Findings

Normal adult PFT values include:

  • FEV1 (Forced Expiratory Volume in 1 second): 80-120% of predicted
  • FVC (Forced Vital Capacity): 80-120% of predicted
  • TLC (Total Lung Capacity): 80-120% of predicted
  • DLCO (Diffusing Capacity for Carbon Monoxide): 75-125% of predicted
  • FEV1/FVC ratio: >0.70-0.75

These values are compared against reference populations adjusted for age, height, sex, and ethnicity 2.

When to Hold Bleomycin: The Evidence-Based Approach

Primary Indications (Symptom-Based)

Hold bleomycin immediately if patients develop:

  • New cough (most sensitive symptom for predicting toxicity) 1
  • New dyspnea 1

It is safer to omit an individual dose in patients with new cough or dyspnea than to risk exacerbating toxicity—this should always be a consultant decision. 1

Diagnostic Workup When Toxicity Suspected

When respiratory symptoms develop:

  1. HRCT chest is the first-line investigation (not PFTs) 1
  2. PFTs may be used as adjunctive tests in cases of diagnostic uncertainty, not as primary screening 1
  3. Chest X-ray has extremely low sensitivity and should NOT be used 1

The Limited Role of PFTs in Bleomycin Monitoring

Critical evidence from the highest-quality study: A prospective phase III randomized trial found that PFTs were only weakly correlated with increased toxicity and only at the end of treatment 1. This is considered Level 1b evidence.

Guideline recommendations state explicitly:

  • PFTs should NOT be used in isolation to aid in decisions about whether to treat with bleomycin 1
  • PFTs should NOT be used as a first-line investigation for suspected lung toxicity 1
  • PFTs may aid diagnosis when there is diagnostic uncertainty, with particular attention to DLCO 1

The Problem with Using PFT Thresholds

Research demonstrates the pitfalls of rigid PFT cutoffs:

  • One study showed that using a 25% reduction in DLCO as a threshold caused 20% of bleomycin doses to be omitted and 30% of patients to receive <two-thirds of planned doses—all without any other evidence of pulmonary toxicity 3
  • Patients who received less than full doses of bleomycin had worse outcomes if they were of good or poor prognosis 3
  • The 25% DLCO reduction threshold appears too cautious and may compromise anti-cancer efficacy 3

Baseline and Monitoring Recommendations

Baseline (before starting bleomycin):

  • Baseline PFTs can be useful as a reference if subsequent toxicity develops, and should be considered where possible 1
  • Patients over age 40 should receive baseline CT thorax (not necessarily HRCT) 1

During treatment:

  • Use a toxicity checklist before and after every cycle 1
  • Check renal function prior to every cycle (declining renal function increases bleomycin toxicity risk) 1, 4
  • Clinical examination and oxygen saturations are more important than routine PFTs 1

Post-treatment:

  • All patients receiving >300 units of bleomycin should receive a post-treatment CT scan 1
  • Further investigations should be symptom-led 1

Risk Factors Requiring Caution (Not Absolute Contraindications)

There are no absolute contraindications to bleomycin, but exercise caution with 1:

  • Age >40 years (especially >70 years) 4
  • Significant smoking history 1, 5
  • Reduced renal function 1, 6
  • Pre-existing lung disease (particularly fibrosis) 1
  • Total dose >400 units 4

Management When Toxicity Confirmed

If lung toxicity is confirmed on HRCT:

  • Cessation of bleomycin may reverse lung damage 1
  • Continuing bleomycin may worsen toxicity 1
  • Consider oral Prednisolone 0.5 mg/kg for 7 days then taper 1
  • Refer to respiratory physician with interest in interstitial lung disease 1
  • Always consider and treat infection (can mimic or coexist with bleomycin toxicity) 1

Key Clinical Pitfall

The most important pitfall is relying on PFT values alone to hold bleomycin. The FDA label notes that "changes in pulmonary function tests are not predictive of the development of pulmonary fibrosis" 4. The guideline evidence is clear that symptoms (cough, dyspnea) and HRCT findings should drive clinical decisions, not isolated PFT abnormalities 1.

References

2
Guideline

general considerations for lung function testing.

European Respiratory Journal, 2005

6
Research

Predictive factors for bleomycin-induced pneumonitis.

The American review of respiratory disease, 1984

Related Questions

What is the recommended bleomycin dosing schedule for germ cell tumors, including dosage per body surface area, cycle frequency, and adjustments for low‑risk versus high‑risk disease and pulmonary risk factors?
Can chemotherapy (chemo) cause pulmonary fibrosis?
What are the common side effects and infection risks after bleomycin therapy in patients with germ cell carcinoma?
When is a pulmonary function test (PFT) indicated prior to administering bleomycin in patients with or without pre-existing lung disease or prior chest radiation?
What baseline pulmonary function test values (forced expiratory volume in 1 second (FEV1), diffusing capacity for carbon monoxide (DLCO), total lung capacity (TLC), forced vital capacity (FVC), and FEV1/FVC ratio) are required to start bleomycin?
What foods should be avoided in a patient with severe liver disease and markedly elevated alanine aminotransferase (ALT) levels?
For a young female with autoimmune encephalitis who did not improve with high‑dose IV methylprednisolone but responded to IVIG, what is the preferred bridging therapy?
What symptoms are associated with an ALT (SGPT) level that is twelve times the upper limit of normal?
Do telmisartan and amlodipine cause itching?
What baseline pulmonary function test values (forced expiratory volume in 1 second (FEV1), diffusing capacity for carbon monoxide (DLCO), total lung capacity (TLC), forced vital capacity (FVC), and FEV1/FVC ratio) are required to start bleomycin?
How should a patient with alanine aminotransferase (ALT/SGPT) levels 12 times the upper limit of normal be managed, including medication?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.